重症流感肺炎危重患者糖皮质激素治疗:倾向评分匹配研究
研究为西班牙148个ICU的前瞻性队列的二次分析,纳入2009年6月至2014年4月确诊流感肺炎的危重患者1846例,排除因病毒肺炎以外原因(如难治性感染性休克、哮喘或慢性阻塞性肺疾病急性加重)使用激素者。604例(32.7%)接受糖皮质激素,最常用甲泼尼龙(578/604,95.7%),中位日剂量相当于甲泼尼龙80 mg(IQR 60-120)、中位疗程7天(IQR 5-10)。粗ICU死亡率激素组27.5% vs 未用组18.8%(p<0.001);倾向评分匹配后激素使用与ICU死亡率相关(Cox HR=1.32,95%CI 1.08-1.60,p<0.006;竞争风险SHR=1.37,95%CI 1.12-1.68,p=0.001)。作者结论为重症流感肺炎使用糖皮质激素与ICU死亡率升高相关,不应作为辅助治疗。
要点
- 重症流感肺炎危重患者中32.7%(604/1846)接受糖皮质激素,最常用甲泼尼龙(578/604,95.7%)。
- 激素中位日剂量相当于甲泼尼龙80 mg(IQR 60-120),中位疗程7天(IQR 5-10)。
- 粗ICU死亡率激素组27.5% vs 未用组18.8%(p<0.001),倾向评分匹配后HR=1.32(95%CI 1.08-1.60)。
- 竞争风险分析SHR=1.37(95%CI 1.12-1.68,p=0.001),方向与Cox分析一致。
- 哮喘、COPD、血液病及需要机械通气与激素使用独立相关;作者结论为不应将激素作为辅助治疗。
适用人群与场景
- 西班牙148个ICU中确诊流感肺炎的危重成人患者,入组时间2009年6月至2014年4月。
- 排除因病毒肺炎以外原因使用糖皮质激素者(如难治性感染性休克、哮喘或COPD急性加重)。
处置流程与药物剂量
- 糖皮质激素以甲泼尼龙最常用(578/604,95.7%),中位日剂量相当于甲泼尼龙80 mg(IQR 60-120),中位疗程7天(IQR 5-10)。
- 作者结论:重症流感肺炎患者不应将糖皮质激素作为辅助治疗。
研究设计与关键结果
- 研究类型:前瞻性队列研究的二次分析,纳入1846例确诊流感肺炎危重患者,来自西班牙148个ICU。
- 604例(32.7%)接受糖皮质激素;激素组粗ICU死亡率27.5% vs 未用组18.8%(p<0.001)。
- 倾向评分匹配后,激素使用与ICU死亡率相关:Cox分析HR=1.32(95%CI 1.08-1.60,p<0.006);竞争风险分析SHR=1.37(95%CI 1.12-1.68,p=0.001)。
- 哮喘、COPD、血液病及需要机械通气与激素使用独立相关。
证据类型、等级与局限
- 证据类型:前瞻性队列研究的二次分析,采用倾向评分匹配控制混杂。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对重症流感肺炎危重患者,本队列显示糖皮质激素使用与ICU死亡率升高相关(匹配后HR=1.32),作者结论为不应作为辅助治疗。
- 使用激素的独立相关因素为哮喘、COPD、血液病及需要机械通气,提示这些患者更可能被处方激素,解读时应考虑适应证混杂。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: To determine clinical predictors associated with corticosteroid administration and its association with ICU mortality in critically ill patients with severe influenza pneumonia.
METHODS: Secondary analysis of a prospective cohort study of critically ill patients with confirmed influenza pneumonia admitted to 148 ICUs in Spain between June 2009 and April 2014. Patients who received corticosteroid treatment for causes other than viral pneumonia (e.g., refractory septic shock and asthma or chronic obstructive pulmonary disease [COPD] exacerbation) were excluded. Patients with corticosteroid therapy were compared with those without corticosteroid therapy. We use a propensity score (PS) matching analysis to reduce confounding factors. The primary outcome was ICU mortality. Cox proportional hazards and competing risks analysis was performed to assess the impact of corticosteroids on ICU mortality.
RESULTS: A total of 1846 patients with primary influenza pneumonia were enrolled. Corticosteroids were administered in 604 (32.7%) patients, with methylprednisolone the most frequently used corticosteroid (578/604 [95.7%]). The median daily dose was equivalent to 80 mg of methylprednisolone (IQR 60-120) for a median duration of 7 days (IQR 5-10). Asthma, COPD, hematological disease, and the need for mechanical ventilation were independently associated with corticosteroid use. Crude ICU mortality was higher in patients who received corticosteroids (27.5%) than in patients who did not receive corticosteroids (18.8%, p < 0.001). After PS matching, corticosteroid use was associated with ICU mortality in the Cox (HR = 1.32 [95% CI 1.08-1.60], p < 0.006) and competing risks analysis (SHR = 1.37 [95% CI 1.12-1.68], p = 0.001).
CONCLUSION: Administration of corticosteroids in patients with severe influenza pneumonia is associated with increased ICU mortality, and these agents should not be used as co-adjuvant therapy.
参考来源
- Moreno G, Rodríguez A, Reyes LF, et al. Corticosteroid treatment in critically ill patients with severe influenza pneumonia: a propensity score matching study. Intensive Care Med. 2018. PMID: 30074052. doi:10.1007/s00134-018-5332-4
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。